Wu Yanan, Hong Qiwei, Lu Fang, Zhang Zhongqiu, Li Jingjing, Nie Zhenlin, He Bangshun
Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Qinhuai District, Nanjing, Jiangsu, China.
Mol Diagn Ther. 2023 May;27(3):283-301. doi: 10.1007/s40291-023-00641-6. Epub 2023 Mar 20.
MicroRNA-155 has been discussed as a biomarker in cancer diagnosis and prognosis. Although relevant studies have been published, the role of microRNA-155 remains uncertain because of insufficient data.
We conducted a literature search in PubMed, Embase, and Web of Science databases to obtain relevant articles and extract data to evaluate the role of microRNA-155 in cancer diagnosis and prognosis.
The pooled results showed that microRNA-155 presented a remarkable diagnostic value in cancers (area under the curve = 0.90, 95% confidence interval (CI 0.87-0.92; sensitivity = 0.83, 95% CI 0.79-0.87; specificity = 0.83, 95% CI 0.80-0.86), which was maintained in the subgroups stratified by ethnicity (Asian and Caucasian), cancer types (breast cancer, lung cancer, hepatocellular carcinoma, leukemia, and pancreatic ductal adenocarcinoma), sample types (plasma, serum, tissue), and sample size (n >100 and n <100). In prognosis, a combined hazard ratio (HR) showed that microRNA-155 was significantly associated with poor overall survival (HR = 1.38, 95% CI 1.25-1.54) and recurrence-free survival (HR = 2.13, 95% CI 1.65-2.76), and was boundary significant with poor progression-free survival (HR = 1.20, 95% CI 1.00-1.44), but not significant with disease-free survival (HR = 1.14, 95% CI 0.70-1.85). Subgroup analyses in overall survival showed that microRNA-155 was associated with poor overall survival in the subgroups stratified by ethnicity and sample size. However, the significant association was maintained in cancer types subgroups of leukemia, lung cancer, and oral squamous cell carcinoma, but not in colorectal cancer, hepatocellular carcinoma, and breast cancer, and was maintained in sample types subgroups of bone marrow and tissue, but not in plasma and serum.
Results from this meta-analysis demonstrated that microRNA-155 was a valuable biomarker in cancer diagnosis and prognosis.
微小RNA-155已被讨论作为癌症诊断和预后的生物标志物。尽管已发表了相关研究，但由于数据不足，微小RNA-155的作用仍不确定。
我们在PubMed、Embase和Web of Science数据库中进行文献检索，以获取相关文章并提取数据，以评估微小RNA-155在癌症诊断和预后中的作用。
汇总结果显示，微小RNA-155在癌症中具有显著的诊断价值（曲线下面积=0.90，95%置信区间（CI）0.87 - 0.92；敏感性=0.83，95%CI 0.79 - 0.87；特异性=0.83，95%CI 0.80 - 0.86），在按种族（亚洲人和白种人）、癌症类型（乳腺癌、肺癌、肝细胞癌、白血病和胰腺导管腺癌）、样本类型（血浆、血清、组织）和样本量（n>100和n<100）分层的亚组中均保持这一结果。在预后方面，合并风险比（HR）显示，微小RNA-155与总体生存率差（HR = 1.38，95%CI 1.25 - 1.54）和无复发生存率差（HR = 2.13，95%CI 1.65 - 2.76）显著相关，与无进展生存率差（HR = 1.20，95%CI 1.00 - 1.44）接近显著相关，但与无病生存率无显著相关（HR = 1.14，95%CI 0.70 - 1.85）。总体生存的亚组分析显示，微小RNA-155在按种族和样本量分层的亚组中与总体生存率差相关。然而，在白血病、肺癌和口腔鳞状细胞癌的癌症类型亚组中保持显著关联，但在结直肠癌、肝细胞癌和乳腺癌中不显著，在骨髓和组织的样本类型亚组中保持显著关联，但在血浆和血清中不显著。
这项荟萃分析的结果表明，微小RNA-155是癌症诊断和预后中有价值的生物标志物。
